一圖看懂中國電力(02380.HK)2020年全年業績
中國電力(02380.HK)公佈其2020年度業績,期內集團收入達284.28億元人民幣(單位下同),同比增長2.39%;年度淨利潤29.26億元,同比增長32.91%;公司權益擁有人應占淨利潤17.08億元,同比增長33.01%;每股盈利0.17元,末期股息每股0.13元。
收入及利潤增加主要由於年內水電板塊的利潤大幅上升;新增風力及光伏發電等新清潔能源項目公司的收入和利潤貢獻;以及燃煤發電的單位燃料成本下降。未來五年內,隨着集團在建的清潔能源項目陸續投產,預計集團的收入和清潔能源的裝機容量佔比均實現大幅提升。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.